ARINGAGE
Live / Registered — Registered (as of 28 Jan 2020)
What this means for you
Registered since 28 Jan 2020. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 87900878
- Registration number
- 5970134
- Mark type
- Stylized text
- Filed
- 30 Apr 2018
- Published for opposition
- 12 Nov 2019
- Registered
- 28 Jan 2020
- Attorney of record
- Miriam D. Trudell
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and veterinary preparations for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; sanitary preparations for medical purposes; biotechnological preparations for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; biological preparations for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; drugs for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; pharmaceuticals for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; multivitamins preparations; pharmaceutical preparations for diagnosis for medical orveterinary purposes; nutraceutical preparations for therapeutic or medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; preparations of microorganisms for medical and veterinary use for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; antibiotics
Owner
- CMG Pharmaceutical Co.,Ltd., Gangnam-gu, Seoul, KR
- CMG Pharmaceutical Co.,Ltd., Gangnam-gu, Seoul, KR
- CMG Pharmaceutical Co.,Ltd., Gangnam-gu, Seoul, KR
Prosecution history
- 28 Jan 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 14 Nov 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 14 Nov 2024 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
- 14 Nov 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 14 Nov 2024 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 28 Jan 2020 — REGISTERED-PRINCIPAL REGISTER
- 12 Nov 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 12 Nov 2019 — PUBLISHED FOR OPPOSITION
- 23 Oct 2019 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 05 Oct 2019 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 26 Sept 2019 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 25 Sept 2019 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 25 Sept 2019 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 11 Jul 2019 — NOTIFICATION OF PRIORITY ACTION E-MAILED
- 11 Jul 2019 — PRIORITY ACTION E-MAILED